AARD
Aardvark Therapeutics, Inc.
Price Chart
Latest Quote
$3.68
-0.26 (-6.60%)
Current Price
| Previous Close | $3.94 |
| Open | $3.91 |
| Day High | $3.98 |
| Day Low | $3.66 |
| Volume | 123,528 |
Stock Information
| Shares Outstanding | 21.82M |
| Total Debt | $336K |
| Cash Equivalents | $91.20M |
| Net Income | $-69.87M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $80.28M |
| EPS (TTM) | $-3.21 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-4.91M |
| Income | $-69.87M |
| Book/sh | $3.99 |
| Cash/sh | $4.18 |
| Employees | 40 |
Financial Ratios
| Quick Ratio | 7.86 |
| Current Ratio | 8.06 |
| Debt/Eq | 0.39 |
Returns & Margins
| ROA | -36.54% |
| ROE | -58.79% |
Ownership
| Insider Ownership | 16.15% |
| Institutional Ownership | 56.43% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.14 |
| P/B | 0.92 |
Analyst Data
| Recommendation | buy |
| Target Price | $15.44 |
Technical Indicators
| SMA20 | $4.66 |
| SMA50 | $4.73 |
| SMA200 | $9.71 |
| RSI | 28.71 |
| ATR | 0.4139 |
| Shares Float | 10.91M |
| Short Float | 7.03% |
| Short Ratio | 5.95 |
| Rel Volume | 0.68 |
Performance History
| Week | -10.46% |
| Month | -37.52% |
| Quarter | -37.09% |
| 6 Months | -69.15% |
| YTD | -72.10% |
| Year | -68.55% |
| 10 Years | -74.28% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $3.68 | 130,596 |
| 2026-06-04 | $3.94 | 91,100 |
| 2026-06-03 | $3.81 | 149,500 |
| 2026-06-02 | $3.97 | 158,000 |
| 2026-06-01 | $3.99 | 170,700 |
| 2026-05-29 | $4.11 | 149,100 |
| 2026-05-28 | $4.20 | 140,700 |
| 2026-05-27 | $3.99 | 210,000 |
| 2026-05-26 | $4.20 | 216,300 |
| 2026-05-22 | $4.54 | 136,800 |
| 2026-05-21 | $4.51 | 166,500 |
| 2026-05-20 | $4.29 | 173,200 |
| 2026-05-19 | $4.37 | 135,100 |
| 2026-05-18 | $4.36 | 289,400 |
| 2026-05-15 | $4.57 | 744,700 |
| 2026-05-14 | $6.73 | 166,800 |
| 2026-05-13 | $6.59 | 172,600 |
| 2026-05-12 | $6.11 | 181,900 |
| 2026-05-11 | $5.72 | 152,600 |
| 2026-05-08 | $5.44 | 84,000 |
| 2026-05-07 | $5.60 | 126,200 |
| 2026-05-06 | $5.89 | 137,300 |
About Aardvark Therapeutics, Inc.
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
đ° Latest News
Several Insiders Invested In Aardvark Therapeutics Flagging Positive News
Simply Wall St. âĸ 2026-05-28T10:14:18Z
Sector Update: Healthcare Stocks Decline Late Afternoon
MT Newswires âĸ 2026-05-15T19:52:02ZTop Midday Decliners
MT Newswires âĸ 2026-05-15T18:20:29ZFDA hold puts Aardvark Prader-Willi drug in limbo
BioPharma Dive âĸ 2026-05-15T11:58:00Z
Discover 3 Promising Penny Stocks With Market Caps Over $100M
Simply Wall St. âĸ 2026-04-17T12:05:17Z
Why Aardvark Therapeutics (AARD) Paused Late-Stage ARD-101 Trials After Cardiac Findings
Insider Monkey âĸ 2026-03-29T20:42:32Z
A Look At Aardvark Therapeutics (AARD) Valuation After The Voluntary Pause Of Its Phase 3 HERO Trial
Simply Wall St. âĸ 2026-03-05T02:21:51Z
Aardvark Therapeutics (AARD) Is Down 61.4% After Pausing Phase 3 HERO Trial Over Cardiac Safety Questions
Simply Wall St. âĸ 2026-03-04T00:22:59Z
Why Aardvark Therapeutics Just Lost More Than Half Its Value
Investor's Business Daily âĸ 2026-03-02T21:28:56Z
Sector Update: Health Care Stocks Retreat Late Afternoon
MT Newswires âĸ 2026-03-02T20:58:02Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $62,725,000 | $22,668,000 | $6,653,000 | $10,874,000 |
| Other Income Expense | $-5,000 | $-334,000 | $-1,978,000 | $-2,810,000 |
| Net Non Operating Interest Income Expense | $5,139,000 | $2,414,000 | $1,423,000 | $120,000 |
| Operating Expense | $62,725,000 | $22,668,000 | $6,653,000 | $10,874,000 |
| General And Administrative Expense | $13,789,000 | $5,305,000 | $2,173,000 | $2,702,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-57,591,000 | $-20,588,000 | $-7,208,000 | $-13,564,000 |
| Net Interest Income | $5,139,000 | $2,414,000 | $1,423,000 | $120,000 |
| Interest Income | $5,139,000 | $2,414,000 | $1,423,000 | $120,000 |
| Normalized Income | $-57,586,000 | $-20,254,000 | $-5,230,000 | $-10,754,000 |
| Net Income From Continuing And Discontinued Operation | $-57,591,000 | $-20,588,000 | $-7,208,000 | $-13,564,000 |
| Total Operating Income As Reported | $-62,725,000 | $-22,785,000 | $-7,415,000 | $-11,363,000 |
| Net Income Common Stockholders | $-57,591,000 | $-20,588,000 | $-7,208,000 | $-13,564,000 |
| Net Income | $-57,591,000 | $-20,588,000 | $-7,208,000 | $-13,564,000 |
| Net Income Including Noncontrolling Interests | $-57,591,000 | $-20,588,000 | $-7,208,000 | $-13,564,000 |
| Net Income Continuous Operations | $-57,591,000 | $-20,588,000 | $-7,208,000 | $-13,564,000 |
| Pretax Income | $-57,591,000 | $-20,588,000 | $-7,208,000 | $-13,564,000 |
| Special Income Charges | $0 | $-117,000 | $-762,000 | $-489,000 |
| Interest Income Non Operating | $5,139,000 | $2,414,000 | $1,423,000 | $120,000 |
| Operating Income | $-62,725,000 | $-22,668,000 | $-6,653,000 | $-10,874,000 |
| Per Share | ||||
| Diluted EPS | $-2.93 | $-0.96 | $-0.56 | $-1.39 |
| Basic EPS | $-2.93 | $-0.96 | $-0.56 | $-1.39 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-62,684,000 | $-22,318,000 | $-4,675,000 | $-7,954,000 |
| Total Unusual Items | $-5,000 | $-334,000 | $-1,978,000 | $-2,810,000 |
| Total Unusual Items Excluding Goodwill | $-5,000 | $-334,000 | $-1,978,000 | $-2,810,000 |
| Reconciled Depreciation | $36,000 | $16,000 | $0 | $110,000 |
| EBITDA (Bullshit earnings) | $-62,689,000 | $-22,652,000 | $-6,653,000 | $-10,764,000 |
| EBIT | $-62,725,000 | $-22,668,000 | $-6,653,000 | $-10,874,000 |
| Diluted Average Shares | $19,624,626 | $21,384,377 | $12,909,267 | $9,732,784 |
| Basic Average Shares | $19,624,626 | $21,384,377 | $12,909,267 | $9,732,784 |
| Diluted NI Availto Com Stockholders | $-57,591,000 | $-20,588,000 | $-7,208,000 | $-13,564,000 |
| Write Off | $0 | $117,000 | $762,000 | $489,000 |
| Gain On Sale Of Security | $-5,000 | $-217,000 | $-1,216,000 | $-2,321,000 |
| Research And Development | $48,936,000 | $17,363,000 | $4,480,000 | $7,172,000 |
| Selling General And Administration | $13,789,000 | $5,305,000 | $2,173,000 | $2,702,000 |
| Other Gand A | $13,789,000 | $5,305,000 | $2,173,000 | $2,702,000 |
| Provision For Doubtful Accounts | - | $117,000 | $0 | $1,000,000 |
| Other Special Charges | - | - | - | $1,000,000 |
Fetched: 2026-06-02
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $106,633,000 | $-54,643,000 | $-34,802,000 | $-27,923,000 |
| Total Assets | $117,181,000 | $77,507,000 | $10,536,000 | $16,757,000 |
| Total Non Current Assets | $5,295,000 | $3,370,000 | $168,000 | $266,000 |
| Other Non Current Assets | $4,940,000 | $2,635,000 | $13,000 | $14,000 |
| Current Assets | $111,886,000 | $74,137,000 | $10,368,000 | $16,491,000 |
| Other Current Assets | $1,859,000 | $474,000 | $127,000 | $70,000 |
| Cash Cash Equivalents And Short Term Investments | $110,027,000 | $73,663,000 | $9,989,000 | $16,105,000 |
| Cash And Cash Equivalents | $47,051,000 | $61,641,000 | $9,735,000 | $15,559,000 |
| Prepaid Assets | - | $314,000 | $252,000 | $316,000 |
| Debt | ||||
| Total Debt | $441,000 | $779,000 | $162,000 | $262,000 |
| Long Term Debt And Capital Lease Obligation | $0 | $441,000 | $50,000 | $162,000 |
| Current Debt And Capital Lease Obligation | $441,000 | $338,000 | $112,000 | $100,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $10,548,000 | $132,150,000 | $45,338,000 | $44,680,000 |
| Total Non Current Liabilities Net Minority Interest | $0 | $127,223,000 | $43,956,000 | $44,085,000 |
| Current Liabilities | $10,548,000 | $4,927,000 | $1,382,000 | $595,000 |
| Current Deferred Liabilities | $0 | $671,000 | $0 | - |
| Payables And Accrued Expenses | $7,194,000 | $3,693,000 | $1,225,000 | $442,000 |
| Payables | $2,072,000 | $2,298,000 | $1,035,000 | $259,000 |
| Accounts Payable | $2,072,000 | $2,298,000 | $1,035,000 | $259,000 |
| Other Non Current Liabilities | - | $26,000 | $2,000 | $19,000 |
| Equity | ||||
| Common Stock Equity | $106,633,000 | $-54,643,000 | $-34,802,000 | $-27,923,000 |
| Total Equity Gross Minority Interest | $106,633,000 | $-54,643,000 | $-34,802,000 | $-27,923,000 |
| Stockholders Equity | $106,633,000 | $-54,643,000 | $-34,802,000 | $-27,923,000 |
| Gains Losses Not Affecting Retained Earnings | $81,000 | $0 | - | - |
| Other Equity Adjustments | $81,000 | - | - | - |
| Retained Earnings | $-115,918,000 | $-58,327,000 | $-37,739,000 | $-30,531,000 |
| Preferred Securities Outside Stock Equity | $0 | $126,756,000 | $43,904,000 | $43,904,000 |
| Other | ||||
| Ordinary Shares Number | $21,815,353 | $21,688,172 | $21,384,377 | $21,384,377 |
| Share Issued | $21,815,353 | $21,688,172 | $21,384,377 | $21,384,377 |
| Tangible Book Value | $106,633,000 | $-54,643,000 | $-34,802,000 | $-27,923,000 |
| Invested Capital | $106,633,000 | $-54,643,000 | $-34,802,000 | $-27,923,000 |
| Working Capital | $101,338,000 | $69,210,000 | $8,986,000 | $15,896,000 |
| Capital Lease Obligations | $441,000 | $779,000 | $162,000 | $262,000 |
| Total Capitalization | $106,633,000 | $-54,643,000 | $-34,802,000 | $-27,923,000 |
| Additional Paid In Capital | $222,470,000 | $3,684,000 | $2,937,000 | $2,608,000 |
| Capital Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Preferred Stock | $0 | $0 | - | - |
| Long Term Capital Lease Obligation | $0 | $441,000 | $50,000 | $162,000 |
| Current Capital Lease Obligation | $441,000 | $338,000 | $112,000 | $100,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $2,913,000 | $225,000 | $45,000 | $53,000 |
| Current Accrued Expenses | $5,122,000 | $1,395,000 | $190,000 | $183,000 |
| Net PPE | $355,000 | $735,000 | $155,000 | $252,000 |
| Gross PPE | $355,000 | $735,000 | $155,000 | $252,000 |
| Other Properties | $355,000 | $735,000 | $155,000 | $252,000 |
| Other Short Term Investments | $62,976,000 | $12,022,000 | $254,000 | $546,000 |
Fetched: 2026-06-02
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-54,267,000 | $-18,196,000 | $-5,824,000 | $-10,543,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-54,172,000 | $-18,087,000 | $-5,824,000 | $-10,543,000 |
| Cash Flow From Continuing Operating Activities | $-54,172,000 | $-18,087,000 | $-5,824,000 | $-10,543,000 |
| Operating Gains Losses | - | - | $-923,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-95,000 | $-109,000 | - | - |
| Investing Cash Flow | $-49,667,000 | $-11,998,000 | $0 | $-1,000,000 |
| Cash Flow From Continuing Investing Activities | $-49,667,000 | $-11,998,000 | $0 | $-1,000,000 |
| Net Other Investing Changes | - | - | - | $-1,000,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $91,075,000 | $85,000,000 | $0 | $225,000 |
| Financing Cash Flow | $89,249,000 | $81,991,000 | $0 | $225,000 |
| Cash Flow From Continuing Financing Activities | $89,249,000 | $81,991,000 | $0 | $225,000 |
| Net Other Financing Charges | $-2,387,000 | $-3,341,000 | - | - |
| Net Preferred Stock Issuance | $0 | $85,000,000 | $0 | - |
| Preferred Stock Issuance | $0 | $85,000,000 | $0 | - |
| Net Common Stock Issuance | $91,075,000 | $0 | $0 | $225,000 |
| Common Stock Issuance | $91,075,000 | $0 | $0 | $225,000 |
| Other | ||||
| End Cash Position | $47,051,000 | $61,641,000 | $9,735,000 | $15,559,000 |
| Beginning Cash Position | $61,641,000 | $9,735,000 | $15,559,000 | $26,877,000 |
| Changes In Cash | $-14,590,000 | $51,906,000 | $-5,824,000 | $-11,318,000 |
| Proceeds From Stock Option Exercised | $561,000 | $332,000 | $0 | $225,000 |
| Net Investment Purchase And Sale | $-49,572,000 | $-11,889,000 | $0 | - |
| Sale Of Investment | $80,027,000 | $0 | - | - |
| Purchase Of Investment | $-129,599,000 | $-11,889,000 | $0 | - |
| Net PPE Purchase And Sale | $-95,000 | $-109,000 | $0 | - |
| Purchase Of PPE | $-95,000 | $-109,000 | $0 | - |
| Change In Working Capital | $356,000 | $1,573,000 | $-81,000 | $-1,311,000 |
| Change In Other Current Liabilities | $-338,000 | $-198,000 | $-100,000 | $-101,000 |
| Change In Payables And Accrued Expense | $6,654,000 | $2,183,000 | $774,000 | $-804,000 |
| Change In Accrued Expense | $6,415,000 | $1,385,000 | $-2,000 | $-835,000 |
| Change In Payable | $239,000 | $798,000 | $776,000 | $31,000 |
| Change In Account Payable | $239,000 | $798,000 | $776,000 | $31,000 |
| Change In Prepaid Assets | $-5,960,000 | $-412,000 | $-755,000 | $-406,000 |
| Other Non Cash Items | $380,000 | $235,000 | $97,000 | $1,000,000 |
| Stock Based Compensation | $3,948,000 | $439,000 | $313,000 | $412,000 |
| Unrealized Gain Loss On Investment Securities | $5,000 | $217,000 | $1,216,000 | $2,321,000 |
| Provisionand Write Offof Assets | $0 | $117,000 | $762,000 | $489,000 |
| Amortization Of Securities | $-1,306,000 | $-96,000 | $0 | - |
| Depreciation Amortization Depletion | $36,000 | $16,000 | $0 | $110,000 |
| Depreciation And Amortization | $36,000 | $16,000 | $0 | $110,000 |
| Depreciation | $36,000 | $16,000 | $0 | $110,000 |
| Net Income From Continuing Operations | $-57,591,000 | $-20,588,000 | $-7,208,000 | $-13,564,000 |
| Gain Loss On Investment Securities | - | - | $-923,000 | - |
Fetched: 2026-06-02